Clearmind Medicine Sets 1-for-8 Reverse Split for October 5
CMND is trading near its 52-week low of $0.77 (4.6% above the low).
Summary
Clearmind Medicine will implement a 1-for-8 reverse share split effective for trading on October 5, 2026, reducing outstanding shares from 4,059,227 to approximately 507,404.
Key Events · Corporate Governance and Compliance · CMND
-
1-for-8 Reverse Split Announced
Every 8 common shares will be consolidated into 1, effective for Nasdaq trading on Monday, October 5, 2026.
-
Share Count Reduced to ~507K
Issued and outstanding shares will drop from 4,059,227 to approximately 507,404, with fractional shares rounded up to the nearest whole share.
-
Warrants and Options Adjusted
Exercise prices and share counts for all outstanding options and warrants will be proportionately adjusted to reflect the 1-for-8 ratio.
-
New CUSIP Assigned
The ordinary shares will trade under new CUSIP number 185053709 following the split.
Analysis · CMND · Life Sciences
A 1-for-8 share consolidation will shrink Clearmind Medicine's outstanding count from roughly 4.06 million to about 507,000. With the stock already near its 52-week low at $0.81, the reverse split is a direct response to Nasdaq's minimum bid price requirement—preserving the listing but often signaling distress. The company has been burning cash on its CMND-100 alcohol use disorder trial and a recent $2.5 million EV charging acquisition, so the split is part of a broader survival strategy rather than a standalone event.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 36.9% of the 961 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CMND was trading at $0.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.7M. The 52-week trading range was $0.77 to $480.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.